JP2024054192A5 - - Google Patents

Download PDF

Info

Publication number
JP2024054192A5
JP2024054192A5 JP2024015037A JP2024015037A JP2024054192A5 JP 2024054192 A5 JP2024054192 A5 JP 2024054192A5 JP 2024015037 A JP2024015037 A JP 2024015037A JP 2024015037 A JP2024015037 A JP 2024015037A JP 2024054192 A5 JP2024054192 A5 JP 2024054192A5
Authority
JP
Japan
Prior art keywords
compound
crystalline form
sample
solvent
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024015037A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024054192A (ja
Filing date
Publication date
Priority claimed from EP20199934.9A external-priority patent/EP3978474A1/en
Application filed filed Critical
Publication of JP2024054192A publication Critical patent/JP2024054192A/ja
Publication of JP2024054192A5 publication Critical patent/JP2024054192A5/ja
Pending legal-status Critical Current

Links

JP2024015037A 2020-10-02 2024-02-02 医薬化合物の結晶形態 Pending JP2024054192A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20199934.9A EP3978474A1 (en) 2020-10-02 2020-10-02 Crystalline forms of a pharmaceutical compound
EP20199934.9 2020-10-02
PCT/EP2021/077100 WO2022069709A1 (en) 2020-10-02 2021-10-01 Crystalline forms of a pharmaceutical compound
JP2022577645A JP7809655B2 (ja) 2020-10-02 2021-10-01 医薬化合物の結晶形態

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022577645A Division JP7809655B2 (ja) 2020-10-02 2021-10-01 医薬化合物の結晶形態

Publications (2)

Publication Number Publication Date
JP2024054192A JP2024054192A (ja) 2024-04-16
JP2024054192A5 true JP2024054192A5 (cg-RX-API-DMAC7.html) 2026-03-04

Family

ID=72744696

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022577645A Active JP7809655B2 (ja) 2020-10-02 2021-10-01 医薬化合物の結晶形態
JP2024015037A Pending JP2024054192A (ja) 2020-10-02 2024-02-02 医薬化合物の結晶形態

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022577645A Active JP7809655B2 (ja) 2020-10-02 2021-10-01 医薬化合物の結晶形態

Country Status (19)

Country Link
US (2) US12116344B2 (cg-RX-API-DMAC7.html)
EP (3) EP3978474A1 (cg-RX-API-DMAC7.html)
JP (2) JP7809655B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240056628A (cg-RX-API-DMAC7.html)
CN (1) CN116390910A (cg-RX-API-DMAC7.html)
AU (2) AU2021353055B2 (cg-RX-API-DMAC7.html)
BR (2) BR122022018214A2 (cg-RX-API-DMAC7.html)
CA (1) CA3193939C (cg-RX-API-DMAC7.html)
CL (1) CL2023000943A1 (cg-RX-API-DMAC7.html)
DK (1) DK4114826T3 (cg-RX-API-DMAC7.html)
ES (1) ES2964105T3 (cg-RX-API-DMAC7.html)
FI (1) FI4114826T3 (cg-RX-API-DMAC7.html)
IL (2) IL316634A (cg-RX-API-DMAC7.html)
MA (1) MA58885B1 (cg-RX-API-DMAC7.html)
MX (1) MX2023003618A (cg-RX-API-DMAC7.html)
PE (1) PE20240138A1 (cg-RX-API-DMAC7.html)
TW (1) TWI912383B (cg-RX-API-DMAC7.html)
WO (1) WO2022069709A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202310184B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3978474A1 (en) * 2020-10-02 2022-04-06 Azafaros B.V. Crystalline forms of a pharmaceutical compound
IL314212A (en) * 2022-01-10 2024-09-01 Azafaros B V Treatment of GM2 gangliosidosis
EP4209215A1 (en) * 2022-01-10 2023-07-12 Azafaros B.V. Treatment of gm2 gangliosidosis
AU2025214578A1 (en) 2024-02-01 2026-08-13 Azafaros B.V. Treatment of gm1 gangliosidosis
EP4595964A1 (en) 2024-02-01 2025-08-06 Azafaros B.V. Treatment of gm1 gangliosidosis
EP4678174A1 (en) * 2024-07-11 2026-01-14 Azafaros B.V. Nizubaglustat for use in the treatment of lysosomal storage disorders
WO2026013261A1 (en) * 2024-07-11 2026-01-15 Azafaros B.V. Nizubaglustat for use in the treatment of lysosomal storage disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2895490T3 (es) 2014-03-27 2022-02-21 Acad Medisch Ct Iminoazúcares N-(5-(bifen-4-ilmetiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa
US20190195897A1 (en) * 2015-06-24 2019-06-27 Universiteit Leiden Glycosylated metabolites
EP3978474A1 (en) * 2020-10-02 2022-04-06 Azafaros B.V. Crystalline forms of a pharmaceutical compound

Similar Documents

Publication Publication Date Title
JP2024071370A5 (cg-RX-API-DMAC7.html)
JP2024516371A5 (cg-RX-API-DMAC7.html)
RU2382039C2 (ru) Способ получения 2-аминотиазол-5-ароматических карбоксамидов в качестве ингибиторов киназ
JP2021530451A5 (cg-RX-API-DMAC7.html)
JP2023002516A5 (cg-RX-API-DMAC7.html)
JP2014530818A5 (cg-RX-API-DMAC7.html)
RU2017141561A (ru) Производные тетрагидронафтиридинилпропионовой кислоты и их применение
JP2011527299A5 (cg-RX-API-DMAC7.html)
JP2019510034A5 (cg-RX-API-DMAC7.html)
JP2019059781A5 (cg-RX-API-DMAC7.html)
JP2006182786A5 (cg-RX-API-DMAC7.html)
JP2008509953A5 (cg-RX-API-DMAC7.html)
JP2021528488A5 (cg-RX-API-DMAC7.html)
JP2011519910A5 (cg-RX-API-DMAC7.html)
NO20063517L (no) Ny krystallinsk form v av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
JP2017505785A5 (cg-RX-API-DMAC7.html)
JP2019535723A5 (cg-RX-API-DMAC7.html)
RU2015134420A (ru) Кристаллические формы { [1-циано-5-(4-хлорофеноксид)-4-гидроксид-изохинолин-3-карбонил]-амино} -уксусной кислоты
JP2019501879A5 (cg-RX-API-DMAC7.html)
NO20063516L (no) Ny krystallinsk form III av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
RU2016149619A (ru) Химические соединения и их применение для улучшения качества мышц
JP2021167346A5 (cg-RX-API-DMAC7.html)
JP2020528913A5 (cg-RX-API-DMAC7.html)
CN114072404A (zh) Ret选择性抑制剂及其制备方法和用途
JP2018521056A5 (cg-RX-API-DMAC7.html)